Nutriband (NASDAQ:NTRB) Announces Earnings Results

Nutriband (NASDAQ:NTRB) announced its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. The business had revenue of $0.44 million for the quarter. Nutriband had a negative net margin of 448.25% and a negative return on equity of 112.64%.

Nutriband Price Performance

Shares of NTRB opened at $5.97 on Friday. Nutriband has a 1 year low of $2.80 and a 1 year high of $8.63. The stock’s fifty day moving average price is $3.47 and its two-hundred day moving average price is $3.67. The firm has a market cap of $72.60 million, a PE ratio of -2.31 and a beta of 2.03.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. raised its stake in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 202,738 shares of the company’s stock after buying an additional 3,111 shares during the quarter. Vanguard Group Inc. owned about 1.68% of Nutriband worth $1,429,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.70% of the company’s stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.